Some targeted cancer drugs make the body hold on to fluid: puffy eyelids, swollen ankles or, with dasatinib, fluid around the lungs. Swelling is managed with raised legs, support stockings, less salt, sometimes water tablets, and a lower dose if needed. Tell your cancer team promptly about rapid weight gain, new breathlessness, a dry cough, chest pain or one swollen, painful leg.
Fluid retention is among the commonest side effects of imatinib, avapritinib (oedema in 72% of people with GIST in its label, 2% grade 3 or higher) and the MET inhibitors (with tepotinib, oedema led to a dose interruption in 28%, a reduction in 22% and permanent stopping in 8%), and pleural effusion is the characteristic problem of dasatinib (28% at 5 years in first-line use, ELN 2016). The guidance is thin: expert recommendations from the European LeukemiaNet without grades, a Novartis-funded review for MET inhibitors, and general dose-modification rows in the labels. The reader's own team's protocol comes first.
Watching: the imatinib label asks for regular weighing and for unexpected rapid weight gain to be investigated. In the CML studies oedema on imatinib was more likely at higher doses and over 65. Before blaming the drug, other causes are sought: the MET inhibitor review suggests a history, examination of the legs, and tests of kidney, liver and thyroid function or a marker of heart failure. Checking for a clot when one leg swells is ordinary practice that no source read here states.
Supportive care: leg elevation, compression stockings, exercise, less salt, skin and foot care, and a diuretic, which the MET inhibitor review says to consider when swelling interferes with quality of life. The evidence is experience, not trials: ELN says fluid retention on CML drugs is normally manageable and reversible with diuretics but that diuretics have limited benefit for periorbital oedema; the MET inhibitor review says management is empiric, and that in its authors' experience such measures are often only temporarily effective.
Label rules. Imatinib: withhold for severe fluid retention until resolved. Capmatinib and tepotinib: keep the dose at grade 2, and if it is intolerable consider withholding and resuming at a reduced dose; at grade 3 withhold until resolved and resume at a reduced dose; at grade 4 stop permanently. Amivantamab: withhold at grade 3 or 4 until grade 1 or baseline. Avapritinib: withhold at grade 3 or 4 until grade 2 or less. Dasatinib (adults): withhold for a severe reaction until it has resolved or improved, then resume as appropriate at a reduced dose. Apart from imatinib's, these are each label's general rule for adverse reactions.
Dasatinib pleural effusion: cough, breathlessness or chest pain prompt a chest X-ray. Management is interrupting or reducing the dose, with or without diuretics and short courses of steroids, and drainage when severe. ELN 2016 says the drug could be resumed at the same dose after a first episode has resolved, that the next lower dose is advisable after a second, and that switching is preferred if a relapse is symptomatic; recurrence occurs in roughly 70% of cases. ELN 2025 lists recurrent pleural effusions despite dose reductions among the side effects that call for a change of drug. Breathlessness or fainting not explained by an effusion should raise suspicion of pulmonary arterial hypertension.
Two products read on 18 November 2026. Telisotuzumab vedotin (US label only): withhold for grade 2 or higher peripheral oedema until grade 1 or less, resuming at the same dose after a first occurrence and at the next lower dose after a later one. Vimseltinib: periorbital oedema in 60% in the US label (3.6% at grade 3 or 4), with no rule written for it in either label; the US label gives dose reductions to 20 mg and then 14 mg twice weekly, and the EU SmPC says to withhold temporarily when the dose is not tolerated and restart at a reduced dose.
Why: Swelling is common in people with cancer and is not always caused by the treatment; the review notes that cancer treatment might make an existing condition worse.
“Before initiating MET inhibitor treatment, patients should be advised of the likelihood of edema development and assessed for any underlying conditions that might predispose them to developing edema”
Why: The imatinib label says the drug is often associated with oedema and occasionally with serious fluid retention, and asks for regular weighing.
“Weigh and monitor patients regularly for signs and symptoms of fluid retention.”
Novartis, on DailyMed (US National Library of Medicine) 2026
Why: The label lists rapid weight gain, with or without visible swelling, among fluid retention reactions that also include fluid around the lungs and in the abdomen.
“Investigate unexpected rapid weight gain carefully and provide appropriate treatment.”
Novartis, on DailyMed (US National Library of Medicine) 2026
Why: Swelling is common in people with cancer and may not be caused by the treatment. The review says these checks may help to find the cause.
“Lower extremity examination, tests for renal, hepatic, or thyroid function, or markers of heart failure, such as B-type natriuretic peptide, may also help to elucidate the underlying cause”
Why: A clot in a leg vein needs its own treatment and is not managed as drug swelling.
Common practice: No source read for this page states it as a step. The oedema guidance read asks for other causes to be looked for without naming a clot, and the amivantamab label carries a separate warning on venous thromboembolism that applies to its use with lazertinib. It is standard practice in the assessment of leg swelling.
Why: The review lists these as possible approaches and says management is empiric, because how these drugs cause swelling is unclear.
“Multiple approaches may be used, including compression stockings, and lifestyle and dietary changes (Table 2).”
Why: The European LeukemiaNet says fluid retention on CML drugs is normally manageable and reversible with diuretics; the MET inhibitor review's authors find such measures often only temporarily effective.
“Consider use if edema is interfering with quality of life”
Why: Swelling around the eyes on imatinib responds poorly to water tablets.
“Diuretic therapy has limited benefit in periorbital oedema, and its management includes dose modification and ultimately changing to an alternative TKI as necessary.”
Why: The review gives the aim as preventing cellulitis, a skin infection. It does not say what the care should consist of.
“Patients should also be advised about appropriate skin and foot care to prevent secondary cellulitis”
Why: The review's authors find that stopping the drug is frequently the only thing that fully clears this swelling. This is each label's general rule for adverse reactions, which the review applies to oedema; it is not a rule written for oedema.
“Maintain dose level. If intolerable, consider withholding TABRECTA until resolved, then resume TABRECTA at a reduced dose.”
Novartis, on DailyMed (US National Library of Medicine) 2026
Why: The label says fluid retention reactions may be serious or life threatening; its examples of severe ones are fluid around the lungs, around the heart and in the abdomen.
“If a severe non-hematologic adverse reaction develops (such as severe hepatotoxicity or severe fluid retention), Gleevec should be withheld until the event has resolved.”
Novartis, on DailyMed (US National Library of Medicine) 2026
Why: The European LeukemiaNet (2020) notes that effusions on dasatinib may occur even after years of previously uncomplicated treatment.
“Evaluate patients who develop symptoms of pleural effusion or other fluid retention, such as new or worsened dyspnea on exertion or at rest, pleuritic chest pain, or dry cough, promptly with a chest x-ray or additional diagnostic imaging as appropriate.”
Bristol Myers Squibb (E.R. Squibb & Sons), on DailyMed (US National Library of Medicine) 2026
Why: ELN says these effusions are potentially reversible after stopping dasatinib and giving steroids and diuretics, and that drainage is needed in rare instances, usually of grade 3 or 4.
“Management of dasatinib-related pleural effusions includes treatment suspension or reduction of the dose, with or without steroids and diuretics.”
Why: ELN 2016 reports that effusions recur in roughly 70% of cases. ELN 2025 lists recurrent effusions despite dose reductions among the side effects that call for a change of drug.
“If the relapse is symptomatic, even if during the first occurrence of an effusion, switching is the preferred option.”
Why: ELN calls raised pressure in the lung arteries rare on dasatinib but potentially fatal, and says prompt withdrawal of the drug may totally or partially reverse it. The label says to stop dasatinib if it is confirmed.
“The presence of dyspnoea and syncope not explained by pleural effusion should prompt the suspicion of PAH.”
Why: This is the US label's row for peripheral oedema, which it records in 22% of 168 patients (1.8% at grade 3 or 4). The label has no warning section on oedema and gives no reason for the rule. No EU product information was found.
“Withhold EMRELIS until recovery to Grade ≤1.”
Why: Neither label has a rule written for oedema, and neither sets a grade at which to act. The US label gives the same dose steps (20 mg, then 14 mg, twice weekly) without the sentence on withholding, and both stop the drug in people who cannot tolerate 14 mg. In the EU SmPC periorbital oedema led to a dose reduction or interruption in 18% and to permanent discontinuation in 2%.
“If patients are unable to tolerate a 30 mg dose of ROMVIMZA, treatment with ROMVIMZA should be temporarily withheld.”
Deciphera Pharmaceuticals (Netherlands), on the European Medicines Agency website 2026
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Regular weighing, a search for other causes when swelling appears, simple physical measures and a diuretic considered when swelling interferes with quality of life, then a dose change by the label; on dasatinib, a prompt chest X-ray for chest symptoms and interruption or dose reduction for an effusion. None of this is graded and none rests on a randomised trial. The sources differ on how well diuretics work: the European LeukemiaNet (2016) says fluid retention on CML drugs is normally manageable and reversible with diuretics, but of limited benefit around the eyes; the MET inhibitor review (Nishio and colleagues 2022, written with Novartis-funded medical writers) says diuretics are given first in practice, yet in its authors' experience such measures are often only temporarily effective and stopping the drug is frequently the only complete answer. Labels differ on when to hold: capmatinib and tepotinib at grade 3 (and to be considered at intolerable grade 2), amivantamab and avapritinib at grade 3 or 4, imatinib and dasatinib when 'severe'. For recurrent dasatinib effusions, ELN 2016 offers stepwise dose reduction or a switch, and ELN 2025 says recurrence despite dose reductions calls for a change of drug. Of the two labels added on 18 November 2026, telisotuzumab vedotin (US) holds earlier, at grade 2 or higher peripheral oedema; vimseltinib has no rule written for oedema in either label.
Leukemia (Steegmann et al., for the European LeukemiaNet; authors declare honoraria and research funding from the makers of the drugs discussed) 2016 · Leukemia (Apperley et al., for the European LeukemiaNet; meetings funded by the ELN with no commercial funding; panel members declare honoraria and research support from the makers of the drugs discussed) 2025 · Targeted Oncology (Nishio et al.; outline and first draft written by medical writers funded by Novartis, Japan) 2022 · Novartis, on DailyMed (US National Library of Medicine) 2026 · Bristol Myers Squibb (E.R. Squibb & Sons), on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026 · EMD Serono, on DailyMed (US National Library of Medicine) 2025 · Janssen Biotech, on DailyMed (US National Library of Medicine) 2025 · Blueprint Medicines, on DailyMed (US National Library of Medicine) 2026 · AbbVie, on DailyMed (US National Library of Medicine) 2025 · Deciphera Pharmaceuticals, on DailyMed (US National Library of Medicine) 2026 · Deciphera Pharmaceuticals (Netherlands), on the European Medicines Agency website 2026
Where it differs: Imatinib: withhold for severe fluid retention until resolved, then resume as appropriate to the severity. Dasatinib (adults): withhold for a severe non-haematological reaction until resolved or improved, then resume as appropriate at a reduced dose depending on severity and recurrence; its fluid retention warning says to consider dose reduction or treatment interruption. Capmatinib and tepotinib (the general row for other adverse reactions): grade 2, maintain the dose, and if intolerable consider withholding and resuming at a reduced dose; grade 3, withhold until resolved and resume at a reduced dose; grade 4, permanently discontinue (both labels). Amivantamab (other adverse reactions): grade 3, withhold until grade 1 or baseline, resuming at the same dose if recovery is within 1 week, at a reduced dose if after 1 week but within 4 weeks, and stopping permanently if recovery takes longer than 4 weeks; grade 4, withhold until grade 1 or baseline, resume at a reduced dose if recovery is within 4 weeks, and stop permanently if it is not or if a grade 4 reaction recurs. Avapritinib (other adverse reactions): grade 3 or 4, withhold until grade 2 or less, then the same or a reduced dose.
Evidence: Regulatory labels. None of the six labels has a dose-modification row written for oedema itself; imatinib and dasatinib have a fluid retention warning, and the other four apply their general rule for adverse reactions.
Novartis, on DailyMed (US National Library of Medicine) 2026 · Bristol Myers Squibb (E.R. Squibb & Sons), on DailyMed (US National Library of Medicine) 2026 · Novartis, on DailyMed (US National Library of Medicine) 2026 · EMD Serono, on DailyMed (US National Library of Medicine) 2025 · Janssen Biotech, on DailyMed (US National Library of Medicine) 2025 · Blueprint Medicines, on DailyMed (US National Library of Medicine) 2026
Where it differs: One lymphoedema clinic, described in the MET inhibitor review, measures limb volume before treatment and again if swelling develops: a change of 5 to 10% means close monitoring and more than 10% means starting compression. It also uses lymphatic massage and stretching exercises.
Evidence: One centre's practice as reported in a review (funded by Novartis); the review notes that in some patients these methods improved the swelling and in others it resolved only when capmatinib was stopped.
Where it differs: ELN 2016: the same dose after a first episode has resolved, the next lower dose after a second (for example 80 mg from 100 mg a day), then stepwise down to 50 mg a day or a switch to another drug; switching is preferred if a relapse is symptomatic. ELN 2025 does not repeat that scheme: it says adverse events in responding patients can be managed by dose reduction, but that recurrent pleural effusions despite dose reductions and pulmonary hypertension require a change of drug. The dasatinib label says only to consider dose reduction or treatment interruption.
Evidence: Expert recommendation without a grade. ELN 2016 reports recurrence in roughly 70% of cases and grade 3 or 4 effusions in 4%. ELN 2020 gives a 5-year cumulative incidence of 37% and lists older age, twice-daily dosing, cardiac or autoimmune disease, hypertension, high cholesterol and advanced-phase disease as risk factors. ELN 2025, a consensus panel aiming for 75% agreement, gives no incidence figure; its side-effect table marks pleural effusion as frequent on dasatinib and notes that it can occur late.
Leukemia (Steegmann et al., for the European LeukemiaNet; authors declare honoraria and research funding from the makers of the drugs discussed) 2016 · Leukemia (Hochhaus et al., for the European LeukemiaNet; panel members declare research support and honoraria from the makers of the drugs discussed) 2020 · Leukemia (Apperley et al., for the European LeukemiaNet; meetings funded by the ELN with no commercial funding; panel members declare honoraria and research support from the makers of the drugs discussed) 2025 · Bristol Myers Squibb (E.R. Squibb & Sons), on DailyMed (US National Library of Medicine) 2026
Where it differs: Telisotuzumab vedotin (US label; no EU text found): peripheral oedema of grade 2 or higher, withhold until grade 1 or less, then the same dose after a first occurrence and the next lower dose after a later one. Vimseltinib: no oedema rule in either label. The US label gives a table of dose reductions (20 mg, then 14 mg, twice weekly) and permanent discontinuation for those unable to tolerate 14 mg; the EU SmPC adds that treatment should be temporarily withheld when 30 mg is not tolerated and restarted at a reduced dose when the clinical condition improves.
Evidence: Regulatory labels; no trial compares the rules. Telisotuzumab vedotin: peripheral oedema in 22% of 168 patients, 1.8% at grade 3 or 4 (US label). Vimseltinib: periorbital oedema in 60%, peripheral oedema in 33% and face oedema in 31% (US label); periorbital oedema in 63% (EU SmPC); both labels report that higher exposure to the drug went with more oedema.
AbbVie, on DailyMed (US National Library of Medicine) 2025 · Deciphera Pharmaceuticals, on DailyMed (US National Library of Medicine) 2026 · Deciphera Pharmaceuticals (Netherlands), on the European Medicines Agency website 2026
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Peripheral oedema may be a sign of heart dysfunction, and treatment should follow the cause “Peripheral oedema could be a sign of cardiac dysfunction, and treatment must be aetiologically based.” | Expert recommendation; not graded | Leukemia (Steegmann et al., for the European LeukemiaNet; authors declare honoraria and research funding from the makers of the drugs discussed) 2016 |
| Diuretics have limited benefit for periorbital oedema “Diuretic therapy has limited benefit in periorbital oedema, and its management includes dose modification and ultimately changing to an alternative TKI as necessary.” | Expert recommendation; not graded | Leukemia (Steegmann et al., for the European LeukemiaNet; authors declare honoraria and research funding from the makers of the drugs discussed) 2016 |
| Management of MET inhibitor oedema is empiric “Since the exact mechanism by which MET inhibitors induce edema is unclear, management is empiric” | Review by four clinicians; not graded (manuscript preparation funded by Novartis) | Targeted Oncology (Nishio et al.; outline and first draft written by medical writers funded by Novartis, Japan) 2022 |
| Diuretics are given first in practice for MET inhibitor oedema, with leg elevation “In clinical practice, diuretic therapy is administered as first-line treatment and patients are advised to raise their legs to reduce lower limb edema.” | Review by four clinicians; not graded (manuscript preparation funded by Novartis) | Targeted Oncology (Nishio et al.; outline and first draft written by medical writers funded by Novartis, Japan) 2022 |
| Supportive measures are often only temporarily effective for MET inhibitor oedema “The authors’ clinical experience is that such measures are often only temporarily effective, and that discontinuation of MET inhibitor therapy is frequently the only approach to completely resolving drug-induced peripheral edema.” | Authors' clinical experience; not graded (manuscript preparation funded by Novartis) | Targeted Oncology (Nishio et al.; outline and first draft written by medical writers funded by Novartis, Japan) 2022 |
| Dasatinib effusions: typical supportive care, and severe effusions may need drainage and oxygen “Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. Severe pleural effusion may require thoracentesis and oxygen therapy.” | Regulatory label; not graded | Bristol Myers Squibb (E.R. Squibb & Sons), on DailyMed (US National Library of Medicine) 2026 |
| After a second dasatinib effusion, it is advisable to reduce to the next lower dose “in the case of a second episode it is advisable to reduce the dose to the” | Expert recommendation; not graded | Leukemia (Steegmann et al., for the European LeukemiaNet; authors declare honoraria and research funding from the makers of the drugs discussed) 2016 |
| Pleural effusion on dasatinib: 5-year cumulative incidence of 37% “Pleural effusion is primarily associated with dasatinib, with a 5-year cumulative incidence of 37%.” | Expert panel recommendations; this statement is not graded | Leukemia (Hochhaus et al., for the European LeukemiaNet; panel members declare research support and honoraria from the makers of the drugs discussed) 2020 |
| Recurrent pleural effusions despite dose reductions call for a change of drug, not a further dose reduction “These include recurrent pleural effusions despite dose reductions, pulmonary hypertension, venous or arterial occlusive events (VOE or AOE), enterocolitis, serious neurologic conditions (e.g. dementia, Parkinsonism) and immune-mediated myocarditis, hepatitis or nephritis.” | Consensus panel recommendations; this statement is not graded | Leukemia (Apperley et al., for the European LeukemiaNet; meetings funded by the ELN with no commercial funding; panel members declare honoraria and research support from the makers of the drugs discussed) 2025 |
| Tepotinib: withhold at grade 3 and resume at a reduced dose “Withhold TEPMETKO until resolved, then resume TEPMETKO at a reduced dose.” | Regulatory label; not graded | EMD Serono, on DailyMed (US National Library of Medicine) 2025 |
| Amivantamab: withhold at grade 3 until grade 1 or baseline “Withhold RYBREVANT until recovery to ≤ Grade 1 or baseline.” | Regulatory label; not graded | Janssen Biotech, on DailyMed (US National Library of Medicine) 2025 |
| Avapritinib: withhold at grade 3 or 4 until grade 2 or less “Withhold AYVAKIT until improvement to less than or equal to Grade 2. Resume at same dose or reduced dose, as clinically appropriate.” | Regulatory label; not graded | Blueprint Medicines, on DailyMed (US National Library of Medicine) 2026 |
| Imatinib: oedema is usually periorbital or in the legs and was managed with diuretics, supportive measures or a lower dose “Edema was most frequently periorbital or in lower limbs and was managed with diuretics, other supportive measures, or by reducing the dose of Gleevec” | Regulatory label; not graded | Novartis, on DailyMed (US National Library of Medicine) 2026 |
| Telisotuzumab vedotin (US label): after a later occurrence of peripheral oedema, resume at the next lower dose “Resume EMRELIS at the next lower dose level.” | Regulatory label; not graded | AbbVie, on DailyMed (US National Library of Medicine) 2025 |
| Vimseltinib (US label): stop for good in people unable to tolerate 14 mg twice weekly “Permanently discontinue ROMVIMZA in patients who are unable to tolerate 14 mg orally twice weekly.” | Regulatory label; not graded | Deciphera Pharmaceuticals, on DailyMed (US National Library of Medicine) 2026 |
| Vimseltinib (EU SmPC): periorbital oedema is among the commonest reasons for a dose reduction or interruption “frequently observed adverse reactions leading to dose reductions or interruptions were rash (21%), periorbital oedema (18%), increased creatine phosphokinase (CPK) (17%), pruritus (10%), face oedema (7%), generalised oedema (7%), fatigue (6%) and peripheral oedema (5%).” | Regulatory label; not graded | Deciphera Pharmaceuticals (Netherlands), on the European Medicines Agency website 2026 |
Shares Tepotinib, Capmatinib, Telisotuzumab vedotin, Amivantamab.
Shares Tepotinib, Capmatinib, Telisotuzumab vedotin.
Shares Imatinib.
Shares Capmatinib, Amivantamab.
Shares Tepotinib, Capmatinib.